Next Phase Newsletter

The firm manages the investments in innovation for a large integrated delivery network health system with over 15 hospitals and 35,000 providers and employees.  The firm is responsible for sourcing external innovation investments outside of the hospital system, and seeks early-stage co-investment opportunities led by quality lead venture firms, coupled with a strong emphasis on co-development opportunities with early-stage companies where the firm’s expertise in clinical, population health, health insurance services, and digital security can be most value-adding. The firm is open to global opportunities.

Currently, the firm is most interested in investments in digital health, HCIT, and process transformation opportunities, and will consider medical devices (predominantly of the wearables, monitoring types). The firm does not consider therapeutics companies at this time.

The firm is opportunistic, but examples of previous engagements have been in technologies targeting care administration/operations, cancer, cardiology, neuroscience and ALS, and even health-focused cybersecurity.  As the firm heavily weights the ability to be an active co-development partner, it is open to the earliest stage digital health technologies, but companies who have yet to close a Seed round will be considered too early.

The firm does not have specific company or management team requirements.  The Investment Office intends to leverage lead VC due diligence in its co-investment assessments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established international investment banking and financial services firm with global offices is exclusively backed by a family office venture fund with over 20 years of investing in life sciences. The firm’s check sizes greatly vary depending on the deal and stage of development. The firm generally participates in rounds beyond seed stage. The firm actively seeks global opportunities.

The firm is most interested in therapeutics and diagnostics companies, but is also open to reviewing opportunities in medical devices, digital health, and research tools/equipment. Within therapeutics, the firm is excited about NCEs. In terms of disease area of indication, the firm has no particular preference and is opportunistic. The firm will expect to see a working prototype and a clear commercialization pathway established.

The firm places high importance on the management team and the story behind the company. While the firm is open to working with first-time or relatively inexperienced CEOs/management teams, BEP would like to see that the management team has relevant prior experience that will enable the company to successfully grow. The firm seeks to be a hands-on investor and can leverage their suite of services to help their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A US fund of a large Asia-based healthcare-focused venture capital firm seeks to make equity investments into early-stage life science companies. The sweet spot is seed to series B and the typical check size ranges from $5 – $10 million USD. The firm focuses on US, Canada or EU based companies. The firm prefers to co-invest or syndicate with other well-known investors.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics and Medical Technology. Digital Health and purely technology companies are less of interest.

The firm is open to working with entrepreneurs with all experience levels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm in the USA focuses on investments in the healthcare industry. The investment size can vary greatly and is very flexible depending on each company’s needs.  The firm provides venture capital and growth capital to healthcare companies. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management, and it typically invests equity or convertible preferred equity in post series A rounds. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.

The firm will consider investments in therapeutics and medical devices, as well as healthcare IT and services. The firm will not consider companies in pre-clinical stage, and typically invests in companies that are near commercialization and commercialization stage.

The firm focuses on private companies with strong and experienced management team. The firm usually takes a board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading early-stage life science accelerator and venture firm is investing in promising early-stage assets, creates a company around each asset and then directly manages the startup. The firm’s investment sizes vary from $1-40 million. Investments are made at the seed stage or in Series A venture rounds; the firm prefers to be the first institutional investor. The firm has invested in assets sourced throughout the USA and has evaluated investment opportunities globally.

The firm only invests in therapeutics-focused opportunities. For the new fund, the firm has a particular interest in CNS, digital health, oncology and immunology. The firm is interested in preclinical-stage assets and will consider investing in assets as early as the discovery stage.

The firm is open to working with both academic projects and entrepreneurs, and also deprioritized pharma assets. The firm generally does not make new investments into companies any later than the Series A stage. The firm supplies management and technical expertise to develop an asset if the company does not have a full management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm with strong China expertise and global capabilities. Founded in 2017, the firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in Boston, Shanghai, as well as Palo Alto.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A major financial institution based in Western Europe managing venture capital funds totaling to several billion, is significantly focused on life sciences. The firm both invests in venture capital funds and makes direct investments in seed-stage and early-stage companies. Typically the firm invests EUR 0.5-8 million initially, with further capital reserved for follow-on rounds. The firm primarily invests in companies in Europe.

The firm is interested in opportunities in biotech and medical devices, and may potentially invest in digital health. The firm is not interested in diagnostics. The firm has a broad interest in early stage therapeutics (mainly First-In-Class), including small molecules, biologics, cell and gene therapies, and all indication areas including cardiovascular, neurology, and rare diseases. The firm invests from preclinical-stage companies through to Phase II.

The firm prefers to invest in companies based in the country where their headquarters are located, but will consider opportunities elsewhere in Europe: for companies in this country, the firm is typically a lead or co-lead investor, but in other regions the firm prefers to be a follow-on investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.